This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, probability of success, licensing and asset acquisition deals, and an epidemiological overview.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
Published: 02 September 2021
Number of pages:23
Norovirus is an RNA virus of the Caliciviridae family, and a human enteric pathogen that causes inflammation of the intestines and/or stomach, known as acute gastroenteritis. Human noroviruses are the principal cause of pandemic gastroenteritis in people of all age groups.
Worldwide, about one out of every five cases of acute gastroenteritis is caused by norovirus. Norovirus is responsible for approximately 685 million cases of gastroenteritis every year.
Globally, norovirus is estimated to cause approximately 200,000 deaths annually, including an estimated 70,000 child deaths, mainly in developing countries.
The largest proportion of industry-sponsored assets in active clinical development for norovirus are in Phase I. Almost all the clinical products currently in development for norovirus are vaccines, with only one product being a therapeutic agent. These are administered via the oral, intranasal, and percutaneous catheter/injection routes.
The overall likelihood of approval of a Phase I antiviral asset is 13%, and the average probability an asset advances from Phase III is 67.7%. Assets, on average, take 8.5 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.
The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for norovirus have been in the early and mid-phases of development, with 91% of trials in Phase I–II, and only 9% in Phase III–IV.
The US has a substantial lead in the number of norovirus clinical trials globally. Takeda has the highest number of completed clinical trials for norovirus, with 12 trials. Takeda also leads industry sponsors with the highest overall number of clinical trials for norovirus.
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
9 Norovirus outbreaks
9 Challenges for vaccine development
11 PIPELINE DRUGS
15 PROBABILITY OF SUCCESS
16 LICENSING AND ASSET ACQUISITION DEALS
16 Takeda Takes Alliance Route For Norovirus Vaccine
17 CLINICAL TRIAL LANDSCAPE
18 Sponsors by status
19 Sponsors by phase
LIST OF FIGURES
11 Figure 1: Overview of pipeline drugs for norovirus in the US
11 Figure 2: Pipeline drugs for norovirus, by company
11 Figure 3: Pipeline drugs for norovirus, by drug type
12 Figure 4: Pipeline drugs for norovirus, by classification
15 Figure 5: Probability of success in the antiviral pipeline
17 Figure 6: Clinical trials in norovirus
17 Figure 7: Top 10 drugs for clinical trials in norovirus
18 Figure 8: Top 10 companies for clinical trials in norovirus
18 Figure 9: Trial locations in norovirus
19 Figure 10: Norovirus trials status
20 Figure 11: Norovirus trials sponsors, by phase
LIST OF TABLES
13 Table 1: Pipeline drugs for norovirus in the US
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726